As a leading company in the national pharmaceutical industry, Yangzijiang Pharmaceutical has insisted on the highest adjustment of standards, promoted the in-depth reform, and enhanced the development momentum with innovative achievements since the 18th National Party Congress to create a brand name image with the spirit of craftsmanship.
In 2018, six varieties of Yangzijiang Pharmaceutical passed the consistency evaluation to enable the substitution of imported drugs and outshine its counterparts in the country.
The achievement is made from the fact that Yangzijiang Pharmaceutical has always promoted its development through quality and innovation. The company has broken through the talent flow system and attracted more than 1,100 R&D personnel to form a research team led by senior scientists and high-level talents.
Under the support of a strong talent team, Yangzijiang Pharmaceutical has made significant progress in key areas such as traditional Chinese medicine, chemical innovation drugs, high-end generic drugs, and bio-pharmaceuticals by successfully developing a large number of stomach granules, blue scorpion oral liquid, and Baile Mian capsule.
It is also accelerating the development of nearly 200 drugs for major diseases to come up with an echelon of all-round products.
As of October 2018, Yangzijiang Pharmaceutical had 156 inventions granted national invention patents, and 3 scientific research achievements won the second prize of National Science and Technology Progress Award.
In 2018, Yangzijiang Pharmaceutical Group saw its output value, sales, profits and taxes increase by 14.69%, 14.95% and 17.66%, respectively. The main indicators were higher than the average growth rate of the industry, showing a healthy and stable growth trend. The company won the first place in the top 100 list of China's pharmaceutical enterprises, and the first place in the China Quality Award nomination award.
